Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Novel Serum Biomarker Investigated for Early Gastric Cancer Diagnosis

By LabMedica International staff writers
Posted on 03 Nov 2021
Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide. More...
More importantly, most reported GC cases are in developing countries. The high mortality of GC is often due to its nonspecific symptoms and delayed diagnosis.

Early detection is key step in the management of patients and survival improvement. Gastric endoscopy is widely used for GC screening. Magnifying endoscopy (ME) with narrow band imaging (ME-NBI) is also an effective tool for real-time endoscopic diagnosis of early gastric cancer (EGC). However, using these tools, identifying subtle lesions or differentiation between inflammation and early intraepithelial neoplasia is still challenging.

Gastroenterologists at the Shanghai General Hospital (Shanghai, China) enrolled a total of 108 patients who presented with GC between July 2016 and June 2018. The subjects included 38 cases of EGC and 70 cases of advanced gastric cancer (AGC). Also included were 28 patients with low-grade intraepithelial neoplasia (LGN, precancerous group), 37 patients with chronic superficial gastritis (CSG) associated with Helicobacter pylori infection (Hpi), 49 patients with other system malignant tumors (OST) and 178 healthy volunteers (healthy control, HC).

Serum samples from 20 patients with EGC and 20 HCs were selected for polypeptide analysis via mass spectrometry. A nanoliter flow HPLC system, EASY-nLC 1000, with a trap column and a C18 column was used in this study and the analysis was performed using the Orbitrap Elite system (Thermo Scientific, Waltham, MA, USA). To confirm the mass spectrometry results, serum samples from 16 patients with EGC, 16 patients with AGC, and 16 HCs were subjected to immunoblotting against inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4).

The tumor tissues of 20 patients with GC and their adjacent normal tissues were embedded, sectioned, and placed in Leica Bond-Max automatic immunohistochemical machine (Leica Microsystems, Berlin, Germany). The expression profiles of ITIH4 in 312 serum samples, including 26 EGC, 48 AGC, 26 LGN, 37 Hpi, 49 OST, and 126 HC serum samples, were determined using enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA). To determine the expression levels of target molecules in blood, exosomes in serum samples were isolated, identified, and analyzed.

The investigators reported that ITIH4 was identified as a key biomarker in patients with EGC. Its expression level in serum from the EGC group, which showed the highest specificity (94.5%), was significantly higher than those in sera from other GC groups as well as the control. Western blot analysis, immunohistochemical staining, and exosome analysis also confirmed ITIH4 expression in sera from patients with GC, but not in those from healthy individual.

The authors concluded that the serum ITIH4 expression level is a promising biomarker for the early diagnosis of GC. ITIH4 levels in serum samples from patients at the early stage of GC were significantly higher than those in serum samples from patients with GC at the advanced stage or HCs. This finding indicated that serum ITIH4 levels can be a potential biomarker for early stage GC diagnosis. The study was published on October 20, 2021 on the journal Clinica Chimica Acta.

Related Links:
Shanghai General Hospital
Thermo Scientific
Leica Microsystems
R&D Systems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.